Protalix Biotherapeutics Is Eligible To Receive A $20M Milestone Payment From Its Commercial Partner, Chiesi Global Rare Diseases, A Business Unit Of The Chiesi Group, Triggered By Fda Approval Of Elfabrio (Pegunigalsidase Alfa-Iwxj) For Fabry Disease
Protalix Biotherapeutics Is Eligible To Receive A $20M Milestone Payment From Its Commercial Partner, Chiesi Global Rare Diseases, A Business Unit Of The Chiesi Group, Triggered By Fda Approval Of Elfabrio (Pegunigalsidase Alfa-Iwxj) For Fabry Disease
Protalix Biotherapeutics有资格从其商业合作伙伴Chiesi集团旗下的业务部门Chiesi Global Rare Disease获得2000万美元的里程碑式付款，这是由美国食品药品管理局批准Elfabrio（Pegunigalsidase Alfa-iwxj）治疗法布里病而触发的
Protalix Biotherapeutics Is Eligible To Receive A $20M Milestone Payment From Its Commercial Partner, Chiesi Global Rare Diseases, A Business Unit Of The Chiesi Group, Triggered By Fda Approval Of Elfabrio (Pegunigalsidase Alfa-Iwxj) For Fabry Disease
Protalix Biotherapeutics有资格从其商业合作伙伴Chiesi集团旗下的业务部门Chiesi Global Rare Disease获得2000万美元的里程碑式付款，这是由美国食品药品管理局批准Elfabrio（Pegunigalsidase Alfa-iwxj）治疗法布里病而触发的
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。